JP7000458B2 - 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 - Google Patents

長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 Download PDF

Info

Publication number
JP7000458B2
JP7000458B2 JP2019563100A JP2019563100A JP7000458B2 JP 7000458 B2 JP7000458 B2 JP 7000458B2 JP 2019563100 A JP2019563100 A JP 2019563100A JP 2019563100 A JP2019563100 A JP 2019563100A JP 7000458 B2 JP7000458 B2 JP 7000458B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hadsc
composition according
administration
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019563100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519658A (ja
Inventor
マロム，エフド
キメルマン，ナダブ ブレイク
グリンスパン，フリーダ
Original Assignee
ステム セル メディスン リミテッド
マピ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステム セル メディスン リミテッド, マピ ファーマ リミテッド filed Critical ステム セル メディスン リミテッド
Publication of JP2020519658A publication Critical patent/JP2020519658A/ja
Application granted granted Critical
Publication of JP7000458B2 publication Critical patent/JP7000458B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019563100A 2017-05-15 2017-05-15 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 Expired - Fee Related JP7000458B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2017/050535 WO2018211486A1 (en) 2017-05-15 2017-05-15 Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells

Publications (2)

Publication Number Publication Date
JP2020519658A JP2020519658A (ja) 2020-07-02
JP7000458B2 true JP7000458B2 (ja) 2022-02-10

Family

ID=64273438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563100A Expired - Fee Related JP7000458B2 (ja) 2017-05-15 2017-05-15 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療

Country Status (8)

Country Link
US (1) US11413311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624815A4 (cg-RX-API-DMAC7.html)
JP (1) JP7000458B2 (cg-RX-API-DMAC7.html)
CN (1) CN110709091A (cg-RX-API-DMAC7.html)
AU (1) AU2017414803B2 (cg-RX-API-DMAC7.html)
CA (1) CA3062964C (cg-RX-API-DMAC7.html)
IL (1) IL270355B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018211486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
US11167003B2 (en) * 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521796A (ja) 2004-11-29 2008-06-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
JP2013516403A (ja) 2010-01-04 2013-05-13 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
US20170065638A1 (en) 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
JP2020519645A (ja) 2017-05-15 2020-07-02 ステム セル メディスン リミテッド 脂肪組織由来幹細胞による多発性硬化症の治療

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
HK1054507B (zh) 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PT1592384E (pt) 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
KR101378874B1 (ko) 2005-10-13 2014-03-27 안트로제네시스 코포레이션 태반 줄기세포를 이용한 면역 조절
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US8021882B2 (en) 2006-08-24 2011-09-20 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
HUE036745T2 (hu) 2006-11-03 2018-07-30 Multiple Sclerosis Res Center Of New York Csontvelõ eredetû mesenchimális õssejtek, mint a neurális progenitor sejtek forrásai
WO2011041240A1 (en) 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
WO2009115581A2 (en) 2008-03-19 2009-09-24 Cryo-Save Ag Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
CA2740578A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Methods of obtaining cell populations from adipose tissue
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
EP2451943B1 (en) 2009-07-09 2016-11-23 TiGenix, S.A.U. Methods and compositions for use in cellular therapies
US8377885B2 (en) * 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3345998B1 (en) 2010-02-18 2024-08-14 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
MX345730B (es) * 2010-12-17 2017-02-14 Anthrogenesis Corp Células adherentes derivadas del amnios (amdac) para usarse en el tratamiento de enfermedades y trastornos relacionados con el sistema inmunitario.
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
SG2014013676A (en) 2011-09-23 2014-05-29 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
CN104350146A (zh) 2012-03-12 2015-02-11 新加坡国立大学 从间充质细胞制备棕色脂肪组织(bat)
TWI642781B (zh) 2014-02-06 2018-12-01 仲恩生醫科技股份有限公司 具優異細胞保護及免疫調節之ｑｕａｄｒｉ－正之基質細胞
US20190046576A1 (en) 2016-02-12 2019-02-14 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521796A (ja) 2004-11-29 2008-06-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
JP2013516403A (ja) 2010-01-04 2013-05-13 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
US20170065638A1 (en) 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
JP2020519645A (ja) 2017-05-15 2020-07-02 ステム セル メディスン リミテッド 脂肪組織由来幹細胞による多発性硬化症の治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｊｏｕｒｎａｌ ｏｆ Ｔｒａｎｓｌａｔｉｏｎａｌ Ｍｅｄｉｃｉｎｅ，ＢｉｏＭｅｄ Ｃｅｎｔｒａｌ，2009年04月24日，７，29
Ｍｅｄｉａｔｏｒｓ ｏｆ Ｉｎｆｌａｍｍａｔｉｏｎ，Ｈｉｎｄａｗｉ Ｐｕｂｌｉｓｈｉｎｇ，2016年09月28日
Ｎａｔｕｒｅ Ｒｅｖｉｅｗｓ Ｎｅｕｒｏｌｏｇｙ，Ｓｐｒｉｎｇｅｒ Ｎａｔｕｒｅ，2010年04月20日，６，５，247-255

Also Published As

Publication number Publication date
IL270355A (cg-RX-API-DMAC7.html) 2019-12-31
JP2020519658A (ja) 2020-07-02
CA3062964C (en) 2024-11-12
US11413311B2 (en) 2022-08-16
CA3062964A1 (en) 2018-11-22
CN110709091A (zh) 2020-01-17
IL270355B1 (cg-RX-API-DMAC7.html) 2023-02-01
WO2018211486A1 (en) 2018-11-22
AU2017414803B2 (en) 2025-02-13
EP3624815A1 (en) 2020-03-25
EP3624815A4 (en) 2021-01-20
US20200147141A1 (en) 2020-05-14
IL270355B2 (en) 2023-06-01
AU2017414803A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
JP6725413B2 (ja) 炎症の治療のための免疫修飾粒子
EP3478300B1 (en) Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
KR102139267B1 (ko) 펩티드 접합된 입자
JP5909745B2 (ja) 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬
JP2016074696A (ja) グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
JP7602322B2 (ja) 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
JP7000458B2 (ja) 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
JP2020519645A (ja) 脂肪組織由来幹細胞による多発性硬化症の治療
US12178849B2 (en) Autoimmune disease treatment with chemokine-loaded alginate microparticles
JP6573293B2 (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
JP2019516803A (ja) 医薬組成物及び自己免疫疾患の治療におけるその使用
KR102383866B1 (ko) 자가 면역 질병 및 당뇨병의 치료를 위한 바이러스 벡터 및 그의 제조방법 및 응용
US20230218572A1 (en) Compositions and methods for improved mesenchymal stem cell therapy
JP2020527573A (ja) 強皮症関連血管障害を治療または改善するための組成物および方法
US20160022772A1 (en) Cytokine Receptors as Targets for Hypertension Therapy and Methods of Use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211223

R150 Certificate of patent or registration of utility model

Ref document number: 7000458

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees